PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history

Chronic HBV and HCV are progressive diseases leading to cirrhosis and liver transplantation. Persistent viral eradication or suppression can positively affect the natural course of the infection, by preventing disease progression. Since its introduction more than 30 years ago, IFN-α has represented...

Full description

Saved in:
Bibliographic Details
Published inExpert review of anti-infective therapy Vol. 11; no. 5; pp. 459 - 474
Main Authors Degasperi, Elisabetta, Viganò, Mauro, Aghemo, Alessio, Lampertico, Pietro, Colombo, Massimo
Format Journal Article
LanguageEnglish
Published England Taylor & Francis 01.05.2013
Subjects
Antiviral Agents - therapeutic use
antiviral therapy
boceprevir
DNA, Viral - antagonists & inhibitors
Drug Administration Schedule
Drug Therapy, Combination
HBV
HCV
Hepacivirus - drug effects
Hepacivirus - physiology
Hepatitis B Surface Antigens - blood
Hepatitis B virus - drug effects
Hepatitis B virus - physiology
Hepatitis B, Chronic - drug therapy
Hepatitis B, Chronic - immunology
Hepatitis B, Chronic - virology
Hepatitis C, Chronic - drug therapy
Hepatitis C, Chronic - immunology
Hepatitis C, Chronic - virology
Humans
Interferon-alpha - therapeutic use
nucleos(t)ide analogs
PegIFN-α2a
Polyethylene Glycols - therapeutic use
Recombinant Proteins - therapeutic use
Ribavirin - therapeutic use
telaprevir
Treatment Outcome
Viral Load - drug effects
Online AccessGet full text

Cover

Abstract Chronic HBV and HCV are progressive diseases leading to cirrhosis and liver transplantation. Persistent viral eradication or suppression can positively affect the natural course of the infection, by preventing disease progression. Since its introduction more than 30 years ago, IFN-α has represented the foundation of HBV and, lately, anti-HCV treatment. Pegylation of the IFN-α molecule (PegIFN-α2a) has provided improvements in both efficacy and administration schedule, thus becoming part of the standard-of-care regimen for HCV and HBV therapy in the last 10 years. Currently, treatment of finite duration with PegIFN-α2a may achieve a sustained virological response off-treatment and HBsAg seroconversion. PegIFN-α2a will most likely remain the backbone of HCV treatment for the next few years, despite the availability of direct-acting antivirals that are expected to improve cure rates. However, many efforts are concentrated on developing new compounds, with the goal of administrating all oral regimens and eliminating PegIFN from anti-HCV treatment.
AbstractList Chronic HBV and HCV are progressive diseases leading to cirrhosis and liver transplantation. Persistent viral eradication or suppression can positively affect the natural course of the infection, by preventing disease progression. Since its introduction more than 30 years ago, IFN-α has represented the foundation of HBV and, lately, anti-HCV treatment. Pegylation of the IFN-α molecule (PegIFN-α2a) has provided improvements in both efficacy and administration schedule, thus becoming part of the standard-of-care regimen for HCV and HBV therapy in the last 10 years. Currently, treatment of finite duration with PegIFN-α2a may achieve a sustained virological response off-treatment and HBsAg seroconversion. PegIFN-α2a will most likely remain the backbone of HCV treatment for the next few years, despite the availability of direct-acting antivirals that are expected to improve cure rates. However, many efforts are concentrated on developing new compounds, with the goal of administrating all oral regimens and eliminating PegIFN from anti-HCV treatment.Chronic HBV and HCV are progressive diseases leading to cirrhosis and liver transplantation. Persistent viral eradication or suppression can positively affect the natural course of the infection, by preventing disease progression. Since its introduction more than 30 years ago, IFN-α has represented the foundation of HBV and, lately, anti-HCV treatment. Pegylation of the IFN-α molecule (PegIFN-α2a) has provided improvements in both efficacy and administration schedule, thus becoming part of the standard-of-care regimen for HCV and HBV therapy in the last 10 years. Currently, treatment of finite duration with PegIFN-α2a may achieve a sustained virological response off-treatment and HBsAg seroconversion. PegIFN-α2a will most likely remain the backbone of HCV treatment for the next few years, despite the availability of direct-acting antivirals that are expected to improve cure rates. However, many efforts are concentrated on developing new compounds, with the goal of administrating all oral regimens and eliminating PegIFN from anti-HCV treatment.
Chronic HBV and HCV are progressive diseases leading to cirrhosis and liver transplantation. Persistent viral eradication or suppression can positively affect the natural course of the infection, by preventing disease progression. Since its introduction more than 30 years ago, IFN-α has represented the foundation of HBV and, lately, anti-HCV treatment. Pegylation of the IFN-α molecule (PegIFN-α2a) has provided improvements in both efficacy and administration schedule, thus becoming part of the standard-of-care regimen for HCV and HBV therapy in the last 10 years. Currently, treatment of finite duration with PegIFN-α2a may achieve a sustained virological response off-treatment and HBsAg seroconversion. PegIFN-α2a will most likely remain the backbone of HCV treatment for the next few years, despite the availability of direct-acting antivirals that are expected to improve cure rates. However, many efforts are concentrated on developing new compounds, with the goal of administrating all oral regimens and eliminating PegIFN from anti-HCV treatment.
Chronic HBV and HCV are progressive diseases leading to cirrhosis and liver transplantation. Persistent viral eradication or suppression can positively affect the natural course of the infection, by preventing disease progression. Since its introduction more than 30 years ago, IFN-α has represented the foundation of HBV and, lately, anti-HCV treatment. Pegylation of the IFN-α molecule (PegIFN-α2a) has provided improvements in both efficacy and administration schedule, thus becoming part of the standard-of-care regimen for HCV and HBV therapy in the last 10 years. Currently, treatment of finite duration with PegIFN-α2a may achieve a sustained virological response off-treatment and HBsAg seroconversion. PegIFN-α2a will most likely remain the backbone of HCV treatment for the next few years, despite the availability of direct-acting antivirals that are expected to improve cure rates. However, many efforts are concentrated on developing new compounds, with the goal of administrating all oral regimens and eliminating PegIFN from anti-HCV treatment.
Author Colombo, Massimo
Degasperi, Elisabetta
Lampertico, Pietro
Viganò, Mauro
Aghemo, Alessio
Author_xml – sequence: 1
  givenname: Elisabetta
  surname: Degasperi
  fullname: Degasperi, Elisabetta
– sequence: 2
  givenname: Mauro
  surname: Viganò
  fullname: Viganò, Mauro
– sequence: 3
  givenname: Alessio
  surname: Aghemo
  fullname: Aghemo, Alessio
– sequence: 4
  givenname: Pietro
  surname: Lampertico
  fullname: Lampertico, Pietro
– sequence: 5
  givenname: Massimo
  surname: Colombo
  fullname: Colombo, Massimo
BackLink https://www.ncbi.nlm.nih.gov/pubmed/23627852$$D View this record in MEDLINE/PubMed
BookMark eNptkM1OGzEURq0K1BDaRV8AeVkWE_wbD-xKRFokfrqga-uO5w4xmrFT2xHKY_EifaYOCmUBXd27OOdbnCnZCzEgIV84m3Fdz08w-RmXM2k-kANulKpqKed7469MXRnB2YRMc35gTKpTLT6SiZBzYWotDsj1T7y_XN5Uf54E0C4mWlZIS0IoA4ZCY0fdKsXgHV3hGoovPtNzCqGlizMKlLNqi5DoyucS0_YT2e-gz_j55R6SX8uLu8WP6ur2--Xi21XlpNalakXTNM7URqJ23LHaNY1iUnJAo7luBCoBCrhAwTVnrnUcDHMKWNOdMsblIfm6212n-HuDudjBZ4d9DwHjJlsulVFzqWs9okcv6KYZsLXr5AdIW_svwQgc7wCXYs4Ju1eEM_uc1455x0UrzcievGGdL2OVGEoC3__XUDvDh7HuAI8x9a0tsO1j6hIE57OV77W_u-ONgQ
CitedBy_id crossref_primary_10_1128_JVI_01030_16
crossref_primary_10_1111_liv_12701
crossref_primary_10_1371_journal_pone_0105665
crossref_primary_10_1021_acsinfecdis_8b00191
crossref_primary_10_1038_s41598_017_15594_0
crossref_primary_10_1021_acsinfecdis_6b00159
crossref_primary_10_1016_j_jim_2014_05_010
crossref_primary_10_1016_j_cld_2015_06_004
crossref_primary_10_1517_21678707_2015_1086333
crossref_primary_10_3390_biom13081208
crossref_primary_10_1586_1744666X_2014_918848
crossref_primary_10_1248_bpb_b23_00242
crossref_primary_10_3390_vaccines5030024
Cites_doi 10.1053/j.gastro.2005.05.008
10.3851/IMP1466
10.1002/hep.23722
10.1111/j.1478-3231.2005.01134.x
10.1016/S0140-6736(05)17701-0
10.1002/hep.25867
10.1053/j.gastro.2007.02.037
10.1002/hep.22065
10.1111/j.1365-2893.2010.01332.x
10.1016/j.jhep.2007.11.011
10.1002/hep.21781
10.1055/s-2003-37590
10.1016/j.antiviral.2011.12.009
10.1016/S0140-6736(10)60934-8
10.1021/bc000082g
10.1038/nrgastro.2010.101
10.1053/jhep.2001.21747
10.1007/s12072-007-9022-5
10.1002/hep.24555
10.1016/j.jhep.2012.06.025
10.1016/S0168-8278(12)60024-5
10.1056/NEJMoa1104430
10.1053/j.gastro.2004.12.049
10.1056/NEJMoa1012912
10.1002/hep.25606
10.1056/NEJMoa0807650
10.1053/j.gastro.2009.11.025
10.1002/hep.22414
10.1016/S0140-6736(10)61384-0
10.1002/hep.22744
10.1586/eri.09.70
10.1016/j.jhep.2005.05.016
10.1080/00365520600955526
10.1111/j.1365-2036.2010.04263.x
10.1002/hep.21159
10.1056/NEJMoa020047
10.1002/hep.25636
10.1111/j.1478-3231.2009.02080.x
10.1016/j.jhep.2005.04.009
10.3851/IMP1284
10.1053/j.gastro.2006.09.052
10.1056/NEJMoa043470
10.1056/NEJMoa1014463
10.1016/S0168-8278(01)00266-5
10.1056/NEJMoa0806104
10.1002/hep.24136
10.1016/j.jhep.2012.02.010
10.1016/j.jhep.2011.05.022
10.1046/j.1365-2893.2003.00450.x
10.1136/gutjnl-2011-301430
10.1053/j.gastro.2010.08.051
10.1002/hep.22262
10.3109/00365521.2012.694902
10.1111/j.1572-0241.2007.01449.x
10.1002/hep.23844
10.1016/j.jhep.2005.10.003
10.1016/S1590-8658(04)80002-1
10.3851/IMP1841
10.1111/j.1365-2036.2011.04750.x
10.1016/j.jhep.2011.12.007
10.1111/j.1365-2036.2006.02887.x
10.1016/S0168-8278(10)60015-3
10.1055/s-2004-832926
10.1111/j.1365-2036.2005.02453.x
10.1053/j.gastro.2008.10.049
10.1056/NEJMoa1009482
10.1016/j.jcv.2012.01.024
10.1055/s-2004-828674
10.1038/nature04082
10.1002/hep.510300109
10.2165/00003088-200140070-00005
10.1038/nri1604
10.1053/jhep.2003.50148
10.1517/14712598.2011.552906
10.1038/ajg.2010.186
10.1111/j.1478-3231.2010.02283.x
10.1016/S1590-8658(11)60065-0
10.3851/IMP1807
10.1016/S0168-8278(00)00094-5
10.1002/hep.24724
10.1053/j.gastro.2006.02.015
10.1136/gut.2005.089722
10.1016/j.jhep.2011.02.023
10.1056/NEJMoa066403
10.1002/hep.21513
10.1002/hep.23568
10.1111/liv.12057
10.1056/NEJMoa1010494
10.1053/j.gastro.2011.11.025
10.1056/NEJMoa0908014
10.1016/j.jhep.2009.12.028
10.5754/hge11259
10.1002/hep.22760
10.7326/0003-4819-140-5-200403020-00010
10.1016/S0168-8278(11)61368-8
10.1056/NEJMoa040431
10.1111/j.1478-3231.2008.01696.x
10.1002/hep.25749
10.1002/hep.23130
ContentType Journal Article
Copyright 2013 Expert Reviews Ltd 2013
Copyright_xml – notice: 2013 Expert Reviews Ltd 2013
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1586/eri.13.37
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1744-8336
EndPage 474
ExternalDocumentID 23627852
10_1586_eri_13_37
11221546
Genre Article
Journal Article
Review
GroupedDBID ---
0BK
0R~
29G
3V.
4.4
53G
6PF
7RV
7X7
88E
8AO
8FI
8FJ
AAOUU
AAWTL
ABEIZ
ABJNI
ABJXJ
ABLKL
ABUWG
ABXYU
ACGFS
ADBBV
AECIN
AENEX
AEOZL
AESAV
AFKRA
AGDLA
AGMLL
AHMBA
AIJEM
AIYSM
AKBVH
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALQZU
BENPR
BKEYQ
BLEHA
BPHCQ
BVXVI
CCCUG
CCPQU
DU5
EBS
EJD
F5P
FYUFA
H13
HMCUK
HZ~
IAO
IEA
IHR
ITC
KSSTO
KYCEM
M1P
M4Z
MV1
NAPCQ
O9-
OVD
P2P
PQQKQ
PROAC
PSQYO
RFE
RNANH
TBQAZ
TCNNB
TDBHL
TEORI
TFL
TFW
TUROJ
UKHRP
AAGSP
AAHJP
AANCX
AAYXX
ABKMU
ACFRI
ADTKB
AFRVT
AIRBT
AMPGV
CBZEQ
CITATION
DDEWX
DGYZD
EMOBN
LJTGL
PHGZM
PHGZT
ACNPW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
PPXIY
ID FETCH-LOGICAL-c355t-d2bbbc7873e5c1c08cbb40331ae7515b2e42a4a12e21510cdc1a70c4a0bf90013
ISSN 1478-7210
1744-8336
IngestDate Fri Jul 11 10:15:52 EDT 2025
Thu Apr 03 07:09:37 EDT 2025
Tue Jul 01 03:09:20 EDT 2025
Thu Apr 24 23:06:20 EDT 2025
Wed Dec 25 09:04:31 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 5
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c355t-d2bbbc7873e5c1c08cbb40331ae7515b2e42a4a12e21510cdc1a70c4a0bf90013
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
PMID 23627852
PQID 1347463585
PQPubID 23479
PageCount 16
ParticipantIDs crossref_primary_10_1586_eri_13_37
pubmed_primary_23627852
proquest_miscellaneous_1347463585
informaworld_taylorfrancis_310_1586_eri_13_37
crossref_citationtrail_10_1586_eri_13_37
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 5/1/2013
2013-05-00
2013-May
20130501
PublicationDateYYYYMMDD 2013-05-01
PublicationDate_xml – month: 05
  year: 2013
  text: 5/1/2013
  day: 01
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Expert review of anti-infective therapy
PublicationTitleAlternate Expert Rev Anti Infect Ther
PublicationYear 2013
Publisher Taylor & Francis
Publisher_xml – name: Taylor & Francis
References Sun (CIT0035) 2011; 34
CIT0072
CIT0071
CIT0074
CIT0073
CIT0075
Asselah (CIT0076) 2010; 30
Aghemo (CIT0013) 2009; 7
Oliviero (CIT0011) 2011; 43
CIT0070
D’Ambrosio (CIT0005) 2012; 56
Reddy (CIT0065) 2010; 139
Chow (CIT0044) 2005; 42
CIT0083
CIT0082
CIT0085
Foster (CIT0078) 2007; 42
CIT0087
Flamm (CIT0090) 2012; 54
Liu (CIT0099) 2009; 136
CIT0086
D’Ambrosio (CIT0004) 2011; 16
CIT0089
CIT0088
Sonneveld (CIT0101) 2012; 56
Marcellin (CIT0102) 2011; 54
CIT0081
CIT0080
Caliceti (CIT0012) 2004; 36
Oliveri (CIT0020) 2005; 42
Marcellin (CIT0093) 2008; 28
CIT0009
Yu (CIT0100) 2013
Wu (CIT0059) 2012; 93
CIT0010
Aghemo (CIT0096) 2012; 56
Chayama (CIT0110) 2012; 55
CIT0091
Tseng (CIT0057) 2011; 16
Lampertico (CIT0105) 2012; 56
EASL (CIT0001) 2011; 55
CIT0014
CIT0016
CIT0015
CIT0018
CIT0017
CIT0019
Sonneveld (CIT0050) 2012; 56
CIT0021
Piratvisuth (CIT0049) 2011; 53
CIT0023
CIT0022
Thompson (CIT0079) 2010; 139
Liaw (CIT0094) 2013; 33
Marcello (CIT0107) 2006; 131
Hui (CIT0034) 2006; 23
Gish (CIT0042) 2007; 102
Kim (CIT0032) 2012; 8
Viganò (CIT0097) 2009; 14
Sonneveld (CIT0048) 2010; 52
CIT0025
CIT0024
CIT0027
CIT0028
Vezali (CIT0106) 2011; 11
CIT0030
Rijckborst (CIT0041) 2010; 105
Ouzan (CIT0104) 2011; 54
Lampertico (CIT0061) 2012
Rotman (CIT0067) 2010; 31
CIT0036
EASL (CIT0002) 2012; 57
Piratvisuth (CIT0047) 2011
Sonneveld (CIT0058) 2012; 142
Di Marco (CIT0026) 1999; 30
Zeuzem (CIT0108) 2012; 56
CIT0043
Marcellin (CIT0052) 2010; 4
Moucari (CIT0040) 2011; 18
Marcellin (CIT0053) 2008; 48
Cardoso (CIT0095) 2010; 52
Bonino (CIT0037) 2007; 56
CIT0054
Fried (CIT0045) 2008; 47
CIT0056
CIT0055
Aghemo (CIT0006) 2010; 7
van Zonneveld (CIT0092) 2005; 21
Yu (CIT0098) 2009; 29
Karabay (CIT0112) 2012; 24
Roberts (CIT0066) 2009; 50
Ferenci (CIT0069) 2005; 43
Ferenci (CIT0068) 2008; 47
Aghemo (CIT0007) 2010; 138
McHutchison (CIT0084) 2010; 362
Romero-Gómez (CIT0077) 2005; 128
Wang (CIT0031) 2012; 59
CIT0063
CIT0062
Lok (CIT0111) 2012; 366
CIT0064
Prati (CIT0008) 2012; 56
Marcellin (CIT0033) 2010; 51
Aghemo (CIT0003) 2012; 57
Piratvisuth (CIT0029) 2008; 2
Piccolo (CIT0039) 2009; 14
Wong (CIT0046) 2010; 51
Lampertico (CIT0060) 2013; 57
Moucari (CIT0051) 2009; 49
Gane (CIT0109) 2010; 376
CIT0103
Marcellin (CIT0038) 2009; 50
References_xml – ident: CIT0072
  doi: 10.1053/j.gastro.2005.05.008
– volume: 14
  start-page: 1165
  year: 2009
  ident: CIT0039
  publication-title: Antivir. Ther. (Lond.)
  doi: 10.3851/IMP1466
– ident: CIT0055
  doi: 10.1002/hep.23722
– ident: CIT0018
  doi: 10.1111/j.1478-3231.2005.01134.x
– ident: CIT0091
  doi: 10.1016/S0140-6736(05)17701-0
– volume: 56
  start-page: 1681
  year: 2012
  ident: CIT0096
  publication-title: Hepatology
  doi: 10.1002/hep.25867
– year: 2013
  ident: CIT0100
  publication-title: Hepatology
– ident: CIT0080
  doi: 10.1053/j.gastro.2007.02.037
– year: 2011
  ident: CIT0047
  publication-title: Hepatol. Int.
– volume: 47
  start-page: 428
  year: 2008
  ident: CIT0045
  publication-title: Hepatology
  doi: 10.1002/hep.22065
– volume: 24
  start-page: 1296
  year: 2012
  ident: CIT0112
  publication-title: Eur. J. Gastroenterol. Hepatol.
– volume: 18
  start-page: 580
  year: 2011
  ident: CIT0040
  publication-title: J. Viral Hepat.
  doi: 10.1111/j.1365-2893.2010.01332.x
– ident: CIT0022
  doi: 10.1016/j.jhep.2007.11.011
– ident: CIT0081
  doi: 10.1002/hep.21781
– ident: CIT0021
  doi: 10.1055/s-2003-37590
– volume: 93
  start-page: 297
  year: 2012
  ident: CIT0059
  publication-title: Antiviral Res.
  doi: 10.1016/j.antiviral.2011.12.009
– ident: CIT0085
  doi: 10.1016/S0140-6736(10)60934-8
– ident: CIT0015
  doi: 10.1021/bc000082g
– volume: 7
  start-page: 485
  year: 2010
  ident: CIT0006
  publication-title: Nat. Rev. Gastroenterol. Hepatol.
  doi: 10.1038/nrgastro.2010.101
– ident: CIT0062
  doi: 10.1053/jhep.2001.21747
– volume: 2
  start-page: 102
  year: 2008
  ident: CIT0029
  publication-title: Hepatol. Int.
  doi: 10.1007/s12072-007-9022-5
– volume: 54
  start-page: 1015A
  year: 2011
  ident: CIT0104
  publication-title: Hepatology
– ident: CIT0030
  doi: 10.1002/hep.24555
– volume: 57
  start-page: 1326
  year: 2012
  ident: CIT0003
  publication-title: J. Hepatol.
  doi: 10.1016/j.jhep.2012.06.025
– volume: 56
  start-page: S5
  year: 2012
  ident: CIT0108
  publication-title: J. Hepatol.
  doi: 10.1016/S0168-8278(12)60024-5
– volume: 366
  start-page: 216
  year: 2012
  ident: CIT0111
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1104430
– volume: 128
  start-page: 636
  year: 2005
  ident: CIT0077
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2004.12.049
– ident: CIT0086
  doi: 10.1056/NEJMoa1012912
– volume: 56
  start-page: 532
  year: 2012
  ident: CIT0005
  publication-title: Hepatology
  doi: 10.1002/hep.25606
– volume: 54
  start-page: 1010A
  year: 2011
  ident: CIT0102
  publication-title: Hepatology
– ident: CIT0083
  doi: 10.1056/NEJMoa0807650
– volume: 138
  start-page: 386
  year: 2010
  ident: CIT0007
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2009.11.025
– volume: 48
  start-page: 718A
  year: 2008
  ident: CIT0053
  publication-title: Hepatology
  doi: 10.1002/hep.22414
– volume: 376
  start-page: 1467
  year: 2010
  ident: CIT0109
  publication-title: Lancet
  doi: 10.1016/S0140-6736(10)61384-0
– volume: 49
  start-page: 1151
  year: 2009
  ident: CIT0051
  publication-title: Hepatology
  doi: 10.1002/hep.22744
– volume: 7
  start-page: 925
  year: 2009
  ident: CIT0013
  publication-title: Expert Rev. Anti. Infect. Ther.
  doi: 10.1586/eri.09.70
– ident: CIT0071
  doi: 10.1016/j.jhep.2005.05.016
– year: 2012
  ident: CIT0061
  publication-title: Hepatology
– volume: 42
  start-page: 247
  year: 2007
  ident: CIT0078
  publication-title: Scand. J. Gastroenterol.
  doi: 10.1080/00365520600955526
– volume: 31
  start-page: 1018
  year: 2010
  ident: CIT0067
  publication-title: Aliment. Pharmacol. Ther.
  doi: 10.1111/j.1365-2036.2010.04263.x
– ident: CIT0070
  doi: 10.1002/hep.21159
– ident: CIT0063
  doi: 10.1056/NEJMoa020047
– volume: 56
  start-page: 202A
  year: 2012
  ident: CIT0050
  publication-title: Hepatology
  doi: 10.1002/hep.25636
– volume: 29
  start-page: 1485
  year: 2009
  ident: CIT0098
  publication-title: Liver Int.
  doi: 10.1111/j.1478-3231.2009.02080.x
– volume: 43
  start-page: 425
  year: 2005
  ident: CIT0069
  publication-title: J. Hepatol.
  doi: 10.1016/j.jhep.2005.04.009
– volume: 14
  start-page: 789
  year: 2009
  ident: CIT0097
  publication-title: Antivir. Ther. (Lond.)
  doi: 10.3851/IMP1284
– volume: 131
  start-page: 1887
  year: 2006
  ident: CIT0107
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2006.09.052
– ident: CIT0028
  doi: 10.1056/NEJMoa043470
– volume: 139
  start-page: 120.e18
  year: 2010
  ident: CIT0079
  publication-title: Gastroenterology
– ident: CIT0087
  doi: 10.1056/NEJMoa1014463
– ident: CIT0025
  doi: 10.1016/S0168-8278(01)00266-5
– ident: CIT0082
  doi: 10.1056/NEJMoa0806104
– volume: 53
  start-page: 1054
  year: 2011
  ident: CIT0049
  publication-title: Hepatology
  doi: 10.1002/hep.24136
– volume: 57
  start-page: 167
  year: 2012
  ident: CIT0002
  publication-title: J. Hepatol.
  doi: 10.1016/j.jhep.2012.02.010
– volume: 56
  start-page: S207
  year: 2012
  ident: CIT0105
  publication-title: J. Hepatol
– volume: 56
  start-page: 341
  year: 2012
  ident: CIT0008
  publication-title: J. Hepatol.
  doi: 10.1016/j.jhep.2011.05.022
– ident: CIT0027
  doi: 10.1046/j.1365-2893.2003.00450.x
– ident: CIT0043
  doi: 10.1136/gutjnl-2011-301430
– volume: 139
  start-page: 1972
  year: 2010
  ident: CIT0065
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2010.08.051
– volume: 47
  start-page: 1816
  year: 2008
  ident: CIT0068
  publication-title: Hepatology
  doi: 10.1002/hep.22262
– volume: 8
  start-page: 1048
  year: 2012
  ident: CIT0032
  publication-title: Scand J. Gastroenterol.
  doi: 10.3109/00365521.2012.694902
– volume: 102
  start-page: 2718
  year: 2007
  ident: CIT0042
  publication-title: Am. J. Gastroenterol.
  doi: 10.1111/j.1572-0241.2007.01449.x
– volume: 52
  start-page: 1251
  year: 2010
  ident: CIT0048
  publication-title: Hepatology
  doi: 10.1002/hep.23844
– ident: CIT0075
  doi: 10.1016/j.jhep.2005.10.003
– volume: 36
  start-page: S334
  year: 2004
  ident: CIT0012
  publication-title: Dig. Liver Dis.
  doi: 10.1016/S1590-8658(04)80002-1
– volume: 16
  start-page: 629
  year: 2011
  ident: CIT0057
  publication-title: Antivir. Ther. (Lond.)
  doi: 10.3851/IMP1841
– volume: 34
  start-page: 424
  year: 2011
  ident: CIT0035
  publication-title: Aliment. Pharmacol. Ther.
  doi: 10.1111/j.1365-2036.2011.04750.x
– ident: CIT0056
  doi: 10.1016/j.jhep.2011.12.007
– volume: 4
  start-page: 151
  year: 2010
  ident: CIT0052
  publication-title: Hepatol. Int.
– volume: 23
  start-page: 1171
  year: 2006
  ident: CIT0034
  publication-title: Aliment. Pharmacol. Ther.
  doi: 10.1111/j.1365-2036.2006.02887.x
– volume: 51
  start-page: S6
  year: 2010
  ident: CIT0033
  publication-title: J. Hepatol
  doi: 10.1016/S0168-8278(10)60015-3
– ident: CIT0016
  doi: 10.1055/s-2004-832926
– volume: 21
  start-page: 1163
  year: 2005
  ident: CIT0092
  publication-title: Aliment. Pharmacol. Ther.
  doi: 10.1111/j.1365-2036.2005.02453.x
– volume: 136
  start-page: 496
  year: 2009
  ident: CIT0099
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2008.10.049
– ident: CIT0089
  doi: 10.1056/NEJMoa1009482
– ident: CIT0103
  doi: 10.1016/j.jcv.2012.01.024
– ident: CIT0023
  doi: 10.1055/s-2004-828674
– ident: CIT0010
  doi: 10.1038/nature04082
– volume: 30
  start-page: 257
  year: 1999
  ident: CIT0026
  publication-title: Hepatology
  doi: 10.1002/hep.510300109
– ident: CIT0014
  doi: 10.2165/00003088-200140070-00005
– ident: CIT0009
  doi: 10.1038/nri1604
– ident: CIT0019
  doi: 10.1053/jhep.2003.50148
– volume: 11
  start-page: 301
  year: 2011
  ident: CIT0106
  publication-title: Expert Opin. Biol. Ther.
  doi: 10.1517/14712598.2011.552906
– volume: 42
  start-page: 576A
  year: 2005
  ident: CIT0044
  publication-title: Hepatology
– volume: 105
  start-page: 1762
  year: 2010
  ident: CIT0041
  publication-title: Am. J. Gastroenterol.
  doi: 10.1038/ajg.2010.186
– volume: 30
  start-page: 1259
  year: 2010
  ident: CIT0076
  publication-title: Liver Int.
  doi: 10.1111/j.1478-3231.2010.02283.x
– volume: 43
  start-page: S86
  year: 2011
  ident: CIT0011
  publication-title: Digest. Liver Dis.
  doi: 10.1016/S1590-8658(11)60065-0
– volume: 16
  start-page: 677
  year: 2011
  ident: CIT0004
  publication-title: Antivir. Ther. (Lond.)
  doi: 10.3851/IMP1807
– ident: CIT0024
  doi: 10.1016/S0168-8278(00)00094-5
– volume: 55
  start-page: 742
  year: 2012
  ident: CIT0110
  publication-title: Hepatology
  doi: 10.1002/hep.24724
– ident: CIT0074
  doi: 10.1053/j.gastro.2006.02.015
– volume: 56
  start-page: 699
  year: 2007
  ident: CIT0037
  publication-title: Gut
  doi: 10.1136/gut.2005.089722
– volume: 55
  start-page: 245
  year: 2011
  ident: CIT0001
  publication-title: J. Hepatol.
  doi: 10.1016/j.jhep.2011.02.023
– ident: CIT0073
  doi: 10.1056/NEJMoa066403
– ident: CIT0017
  doi: 10.1002/hep.21513
– volume: 51
  start-page: 1945
  year: 2010
  ident: CIT0046
  publication-title: Hepatology
  doi: 10.1002/hep.23568
– volume: 50
  start-page: S336
  year: 2009
  ident: CIT0038
  publication-title: J. Hepatol.
– volume: 33
  start-page: 111
  year: 2013
  ident: CIT0094
  publication-title: Liver Int.
  doi: 10.1111/liv.12057
– ident: CIT0088
  doi: 10.1056/NEJMoa1010494
– volume: 42
  start-page: 577A
  year: 2005
  ident: CIT0020
  publication-title: Hepatology
– volume: 142
  start-page: 513
  year: 2012
  ident: CIT0058
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2011.11.025
– volume: 362
  start-page: 1292
  year: 2010
  ident: CIT0084
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa0908014
– volume: 52
  start-page: 652
  year: 2010
  ident: CIT0095
  publication-title: J. Hepatol.
  doi: 10.1016/j.jhep.2009.12.028
– volume: 59
  start-page: 680
  year: 2012
  ident: CIT0031
  publication-title: Hepatogastroenterology
  doi: 10.5754/hge11259
– ident: CIT0054
  doi: 10.1002/hep.22760
– ident: CIT0064
  doi: 10.7326/0003-4819-140-5-200403020-00010
– volume: 54
  start-page: 541
  year: 2012
  ident: CIT0090
  publication-title: J. Hepatol.
  doi: 10.1016/S0168-8278(11)61368-8
– ident: CIT0036
  doi: 10.1056/NEJMoa040431
– volume: 28
  start-page: 477
  year: 2008
  ident: CIT0093
  publication-title: Liver Int.
  doi: 10.1111/j.1478-3231.2008.01696.x
– volume: 57
  start-page: 890
  year: 2013
  ident: CIT0060
  publication-title: Hepatology
  doi: 10.1002/hep.25749
– volume: 56
  start-page: 199A
  year: 2012
  ident: CIT0101
  publication-title: Hepatology
  doi: 10.1002/hep.25636
– volume: 50
  start-page: 1045
  year: 2009
  ident: CIT0066
  publication-title: Hepatology
  doi: 10.1002/hep.23130
SSID ssj0034952
Score 2.0619733
SecondaryResourceType review_article
Snippet Chronic HBV and HCV are progressive diseases leading to cirrhosis and liver transplantation. Persistent viral eradication or suppression can positively affect...
SourceID proquest
pubmed
crossref
informaworld
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 459
SubjectTerms Antiviral Agents - therapeutic use
antiviral therapy
boceprevir
DNA, Viral - antagonists & inhibitors
Drug Administration Schedule
Drug Therapy, Combination
HBV
HCV
Hepacivirus - drug effects
Hepacivirus - physiology
Hepatitis B Surface Antigens - blood
Hepatitis B virus - drug effects
Hepatitis B virus - physiology
Hepatitis B, Chronic - drug therapy
Hepatitis B, Chronic - immunology
Hepatitis B, Chronic - virology
Hepatitis C, Chronic - drug therapy
Hepatitis C, Chronic - immunology
Hepatitis C, Chronic - virology
Humans
Interferon-alpha - therapeutic use
nucleos(t)ide analogs
PegIFN-α2a
Polyethylene Glycols - therapeutic use
Recombinant Proteins - therapeutic use
Ribavirin - therapeutic use
telaprevir
Treatment Outcome
Viral Load - drug effects
Title PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history
URI https://www.tandfonline.com/doi/abs/10.1586/eri.13.37
https://www.ncbi.nlm.nih.gov/pubmed/23627852
https://www.proquest.com/docview/1347463585
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dbtMwFLbKJiFuEP90g8kgKiFN6RInbhLultBpIK2q0IZ6F9mOUyKxdFpTEDwNr8Ar8AA8E8ex46XQScBNVMVJrPj7cnqOfc5nhF7EIxrGNPQcFsWqJCemDucQrPCYCpILznmsCoVPJqPjs-DtjM56vc_d6pKaD8XXjXUl_4MqnANcVZXsPyBrHwon4DfgC0dAGI5_hfFUzt8cTZxBOh4kHmE2ZfAqe1wljWv5W3AJVfJ0XS73k2bFIG3qnAcpGRyqpeovStFHqw-vrfQ2Wsh1p8QFoCgdk8P1Se7X67IEr-WcKfHx0uSMLdXUbm1t__tyziq1OJ8QXSm0ulxYzs0_yPO26kYl57YNShSySf9uGqelrM1NZrbC6-QGDqW2sGEQOJGvVU-sCfY6VKMdexpoufA_7Dxtlp3gZYaeP9SqMR28L84bwAn8OYeRFsj9TVS7bbqBtgnEF2rri3BmI3UfokZiZKigpwPbj5KONneu-TFrKrfXxyqNz3J6B902wQY-1My5i3qyuodunph0ivtoYgj08zthGB6NAUxsyYMXBTbkwZY8OMFAHpy-wuzHN0MbbGjzAJ0djU_TY8dssOEIcDNrJyfwLQow2b6kwhNuBN9m4Pq-x2QIfi4nMiAsYB6RyjF0RS48FroiYC4vYhU8PERb1aKSjxHORyIG088pDE9AizwSEcl9EoKBz4uokH30sh2uTBj1ebUJysdMRaEwyBkMcub5mR_20XN76YWWXNl0kdMd86xu5rcKvRlN5m-4_lkLSgYGVK2KsUouVstM1VIH4HZHtI8eabRsty3YO9e27KJbVzR_grbqy5V8Cm5qzfcaSu2h7WQ8mb77BdG9k5o
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=PegIFN-%CE%B12a+for+the+treatment+of+chronic+hepatitis+B+and+C%3A+a%C2%A010-year+history&rft.jtitle=Expert+review+of+anti-infective+therapy&rft.au=Degasperi%2C+Elisabetta&rft.au=Vigan%C3%B2%2C+Mauro&rft.au=Aghemo%2C+Alessio&rft.au=Lampertico%2C+Pietro&rft.date=2013-05-01&rft.eissn=1744-8336&rft.volume=11&rft.issue=5&rft.spage=459&rft_id=info:doi/10.1586%2Feri.13.37&rft_id=info%3Apmid%2F23627852&rft.externalDocID=23627852
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1478-7210&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1478-7210&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1478-7210&client=summon